Cd81 Interacts with the T Cell Receptor to Suppress Signaling
Author
Cevik, S.I.
Keskin, N.
Belkaya, S.
Ozlu, M.I.
Deniz, E.
Tazebay, U.H.
Erman, B.
Date
2012Source Title
PLoS ONE
Print ISSN
19326203
Volume
7
Issue
11
Language
English
Type
ArticleItem Usage Stats
141
views
views
127
downloads
downloads
Abstract
CD81 (TAPA-1) is a ubiquitously expressed tetraspanin protein identified as a component of the B lymphocyte receptor (BCR) and as a receptor for the Hepatitis C Virus. In an effort to identify trans-membrane proteins that interact with the T-cell antigen receptor (TCR), we performed a membrane yeast two hybrid screen and identified CD81 as an interactor of the CD3delta subunit of the TCR. We found that in the absence of CD81, in thymocytes from knockout mice, TCR engagement resulted in stronger signals. These results were recapitulated in T cell lines that express low levels of CD81 through shRNA mediated silencing. Increased signaling did not result from alterations in the levels of TCR on the surface of T lymphocytes. Although CD81 is not essential for normal T lymphocyte development, it plays an important role in regulating TCR and possibly pre-TCR signal transduction by controlling the strength of signaling. CD81 dependent alterations in thymocyte signaling are evident in increased CD5 expression on CD81 deficient double positive (DP) thymocytes. We conclude that CD81 interacts with the T cell receptor to suppress signaling. © 2012 Cevik et al.
Keywords
CD3 antigenCD5 antigen
CD81 antigen
short hairpin RNA
T lymphocyte receptor
T lymphocyte receptor delta chain
antigen function
article
cell maturation
controlled study
gene rearrangement
gene silencing
human
human cell
immunoregulation
intracellular signaling
lymphocyte differentiation
lymphocyte proliferation
nucleotide sequence
protein determination
protein expression
protein protein interaction
thymocyte
two hybrid system
Animals
Antigens, CD5
Antigens, CD81
Cell Communication
Gene Expression
HEK293 Cells
Humans
Lymphocyte Activation
Mice
Mice, Knockout
Plasmids
Protein Binding
Receptors, Antigen, T-Cell, gamma-delta
RNA, Small Interfering
Signal Transduction
Thymocytes
Transfection
Two-Hybrid System Techniques
Hepatitis C virus
Mus
Permalink
http://hdl.handle.net/11693/21250Published Version (Please cite this version)
http://dx.doi.org/10.1371/journal.pone.0050396Collections
Related items
Showing items related by title, author, creator and subject.
-
Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment
Cekic, C.; Linden J. (American Association for Cancer Research Inc., 2014)Adenosine A2A receptor (A2AR) blockade enhances innate and adaptive immune responses. However, mouse genetic studies have shown that A2AR deletion does not inhibit the growth of all tumor types. In the current study, we ... -
Biological properties of extracellular vesicles and their physiological functions
Yáñez-Mó, M.; Siljander, P. R. M.; Andreu, Z.; Zavec, A. B.; Borràs, F. E.; Buzas, E. I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; Colás, E.; Cordeiro-Da, S. A.; Fais, S.; Falcon-Perez, J. M.; Ghobrial, I. M.; Giebel, B.; Gimona, M.; Graner, M.; Gursel, I.; Gursel, M.; Heegaard, N. H. H.; Hendrix, A.; Kierulf, P.; Kokubun, K.; Kosanovic, M.; Kralj-Iglic, V.; Krämer-Albers, E. M.; Laitinen, S.; Lässer, C.; Lener, T.; Ligeti, E.; Line, A.; Lipps, G.; Llorente, A.; Lötvall, J.; Manček-Keber, M.; Marcilla, A.; Mittelbrunn, M.; Nazarenko, I.; Nolte-'t Hoen, E. N. M.; Nyman, T. A.; O'Driscoll, L.; Olivan, M.; Oliveira, C.; Pállinger, E.; Del Portillo, H. A.; Reventós, J.; Rigau, M.; Rohde, E.; Sammar, M.; Sánchez-Madrid, F.; Santarém, N.; Schallmoser, K.; Ostenfeld, M. S.; Stoorvogel, W.; Stukelj, R.; Grein V. D. S.G.; Helena,ü V. M.; Wauben, M. H. M.; De Wever, O. (Taylor & Francis, 2015)In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and ... -
Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade
Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...